Atezolizumab Plus Standard Care Improves Survival in Advanced Cervical Cancer
By Elana Gotkine HealthDay Reporter
FRIDAY, Jan. 5, 2024 -- For patients with metastatic, persistent, or recurrent cervical cancer, adding atezolizumab to a standard bevacizumab plus platinum regimen significantly improves progression-free and overall survival, according to a study published in the January issue of The Lancet.
Ana Oaknin, M.D., from the Vall d'Hebron Institute of Oncology in Barcelona, Spain, and colleagues conducted a randomized, phase 3 trial involving 410 patients from 92 sites in Europe, Japan, and the United States with metastatic, persistent, or recurrent cervical cancer that was measurable, previously untreated, and not amenable to curative surgery or radiation. Participants were randomly assigned to receive standard therapy (cisplatin, paclitaxel, and bevacizumab) with or without atezolizumab 1,200 mg.
The researchers found that median progression-free survival was 13.7 and 10.4 months with atezolizumab and standard therapy, respectively (hazard ratio, 0.62). Median overall survival at the interim overall survival analysis was 32.1 and 22.8 months, respectively (hazard ratio, 0.68). Overall, 79 and 75 percent of patients in the experimental and standard groups, respectively, had grade 3 or worse events. Increases in grade 1 to 2 diarrhea, arthralgia, pyrexia, and rash were seen with atezolizumab.
"We believe that atezolizumab with bevacizumab and platinum-based chemotherapy should be considered as a new first-line option for patients with metastatic, persistent, or recurrent cervical cancer," the authors write.
Several authors disclosed ties to pharmaceutical companies, including F. Hoffmann-La Roche, which manufactures atezolizumab and funded the trial.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
AACR: At-Home HPV Testing Boosts Cervical Cancer Screening Participation
FRIDAY, April 12, 2024 -- Mailed at-home self-sampling for human papillomavirus (HPV) testing increases cervical cancer screening participation in underscreened...
Cervical Cancer Screening Lower in Rural Than Urban Health Centers
MONDAY, March 25, 2024 -- Up-to-date cervical cancer screening is lower in rural than urban community health centers (CHCs), with the differences mainly due to CHC-level...
Simple Hysterectomy Not Inferior for Pelvic Recurrence in Cervical Cancer
THURSDAY, Feb. 29, 2024 -- For patients with low-risk cervical cancer, simple hysterectomy is not inferior to radical hysterectomy with respect to incidence of pelvic recurrence...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.